%0 Journal Article %A Zhao, Baohong %D 2018 %I Begell House %K TNF, osteoclasts, bone resorption, inflammation %N 4 %P 253-261 %R 10.1615/CritRevImmunol.2018025874 %T Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption? %U https://www.dl.begellhouse.com/journals/2ff21abf44b19838,33ef53647edb3659,67fc275e17c28bd6.html %V 38 %X Chronic inflammation is one of the most evident and common pathological conditions leading to deregulated osteoclastogenesis and bone remodeling. Tumor necrosis factor (TNF) as a pleiotropic cytokine plays a key role, not only in inflammation, but also in bone erosion in diseases associated with bone loss. TNF can stimulate the proliferation of osteoclast precursors and, in most conditions, act together with other cytokines and growth factors such as receptor activator of nuclear factor (NF)-[kappa]B ligand (RANKL), interleukin-6, and transforming growth factor beta to synergistically promote osteoclast formation and bone resorption in vivo. A longstanding enigma in the field is why TNF alone is not able to induce osteoclast differentiation as effectively as the same superfamily member RANKL, a physiological master osteoclastogenic cytokine. Recent studies have highlighted several lines of evidence showing the intrinsic mechanisms through RBP-J, NF-[kappa]B p100/TNF receptor-associated factor 3, or interferon regulatory factor-8 that restrain TNF-induced osteoclast differentiation and bone resorption. These feedback inhibitory mechanisms driven by TNF shed light into the current paradigm of osteoclastogenesis and would provide novel therapeutic implications on controlling inflammatory bone resorption. %8 2018-07-23